{"id":"W3216996692","doi":"10.1093/neuonc/noab196.233","title":"CTNI-08. DB102-01 ENGAGE STUDY: A BIOMARKER-GUIDED, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE 3 CLINICAL TRIAL OF DB102 IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)","year":2021,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Temozolomide; Placebo; Internal medicine; Biomarker; Clinical endpoint; Oncology; Surrogate endpoint; Clinical trial; Phases of clinical research; Progression-free survival; Randomized controlled trial; Radiation therapy; Chemotherapy; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002493916,0.002614952,0.002633412,0.0005517963,0.0007031722,0.001405894,0.001208414,0.002841788,0.007149583],"category_scores_gemma":[0.001550592,0.0007311218,0.001679196,0.0005429341,0.001320629,0.001143549,0.0004622657,0.003852656,0.001478267],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000896039,"about_ca_system_score_gemma":0.001992472,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000981056,"about_ca_topic_score_gemma":0.003462635,"domain_scores_codex":[0.9990731,0.0005460596,0.0000466169,0.0001337519,0.00007895505,0.0001214286],"domain_scores_gemma":[0.9989583,0.0001634177,0.0002986118,0.0000905304,0.00009256774,0.0003964625],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9719595,0.0106288,0.0005153159,0.0004926841,0.0005714996,0.00002977963,0.00003180172,0.0002225079,0.005555328,0.0001634883,0.001680351,0.008149047],"study_design_scores_gemma":[0.9263945,0.07071487,0.0009147344,0.00002344636,0.0002668164,0.00002240859,0.00001104986,0.0002374826,0.0005056523,0.0001136193,0.0007814068,0.00001400584],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.96165,0.005305998,0.001374836,0.001928957,0.00110509,0.01822767,0.004108239,0.0004688204,0.005830365],"genre_scores_gemma":[0.944289,0.003360248,0.00502241,0.00426221,0.00108801,0.02865873,0.005008898,0.00009595425,0.008214646],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007149583,"threshold_uncertainty_score":0.02391773,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0727596786582985,"score_gpt":0.3900084116739805,"score_spread":0.317248733015682,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}